In the space of 3 days and in the same week as announcing the appointment of its new CEO J. Donald deBethizy, Danish biotech Santaris Pharma has revealed a trio of deals centred on its RNA-targeting locked nucleic acid (LNA) drug platform. Isarna Therapeutics has gained access to the technology to optimise oligonucleotide immunotherapeutics targeted against the cytokine transforming growth factor β (TGF-β). Santaris has also formed a global alliance with Roche for the discovery of LNA drugs against multiple targets across several disease areas and partnered with GlaxoSmithKline for a second time in an option-based deal.